Does Humana Cover Lantus (Insulin Glargine)?

What Is Lantus and Why Humana Coverage Matters

Lantus is a brand-name long-acting basal insulin manufactured by Sanofi that contains insulin glargine 100 units/mL. It has been an anchor of type 1 and type 2 diabetes management since its FDA approval in April 2000 [1]. The insulin provides approximately 24 hours of peakless, flat-action glucose lowering after a single subcutaneous injection, which makes it the most widely prescribed basal insulin in the United States [2].

Because basal insulin is a daily medication that patients depend on to survive, insurer formulary decisions carry real clinical weight. Humana is one of the three largest Medicare Advantage carriers in the country, covering approximately 5.8 million Medicare Advantage enrollees as of 2024 [3]. Its formulary decisions affect millions of patients with diabetes who rely on Lantus every day.

The ORIGIN trial (N=12,537), published in the New England Journal of Medicine in 2012, established that insulin glargine titrated to a fasting plasma glucose target of 95 mg/dL or less did not increase cardiovascular events compared with standard care over a median follow-up of 6.2 years [4]. That cardiovascular safety data underpins guideline support for long-term basal insulin use and is directly relevant to coverage arguments when insurers try to limit access.

Humana's coverage of Lantus is not a single yes-or-no answer. It depends on whether the patient has a Humana commercial plan, a Humana Medicare Advantage Prescription Drug (MA-PD) plan, or a Humana standalone Part D plan. Each plan publishes its own formulary, and formularies can change every January 1.

How to Look Up Your Specific Humana Formulary Tier for Lantus

Every Humana plan posts a current formulary, called the List of Covered Drugs, on Humana's plan finder and on Medicare.gov. Patients should search the plan's formulary PDF for "insulin glargine" or "Lantus" every year during Open Enrollment (October 15 through December 7).

On most 2024 Humana commercial plans, Lantus sits at Tier 3 (preferred brand) with a copay ranging from $45 to $80 per 30-day fill at preferred pharmacies. On Humana Medicare Advantage plans, Lantus commonly appears at Tier 3 or Tier 4 with a copay or coinsurance between $45 and $100 in the initial coverage phase, rising in the coverage gap [5].

The Inflation Reduction Act of 2022 capped out-of-pocket insulin costs at $35 per month for Medicare Part D enrollees beginning January 2023 [6]. That cap applies to all covered insulins, including Lantus, on any Humana Part D or MA-PD plan. Patients who are paying more than $35 per month for Lantus through Humana Medicare should contact 1-800-HUMANA immediately.

The American Diabetes Association 2024 Standards of Care state: "For patients who require insulin, access to affordable insulin is a critical component of diabetes management, and clinicians should be aware of all available cost-reduction strategies" [7]. That guidance gives prescribers a documented clinical rationale to push back on formulary restrictions.

Prior Authorization Criteria for Lantus on Humana Plans

Prior authorization (PA) is required for Lantus on most Humana Medicare Advantage plans and on some commercial plans. Knowing the exact criteria before submitting saves days of delay.

For Humana MA-PD plans, the standard prior authorization criteria for Lantus generally require all of the following: a confirmed diagnosis of type 1 or type 2 diabetes with ICD-10 codes E10.x or E11.x, a prescriber who is a licensed physician or advanced practice provider with prescribing authority, and documentation that a biosimilar insulin glargine (Basaglar, Semglee, or Rezvoglar) was either tried and failed or is medically contraindicated [8]. Failure documentation should include dates of use, doses, and the specific reason the biosimilar was inadequate, such as hypersensitivity, inadequate glycemic control at equivalent doses, or patient-specific device incompatibility.

For type 1 diabetes patients, contraindication documentation is usually straightforward because glycemic stability with a specific device and insulin concentration matters enormously. For type 2 diabetes patients, the step-therapy hurdle is higher, and the PA package should also include a recent HbA1c, a current medication list, and any relevant comorbidities such as chronic kidney disease that affect insulin choice [9].

Humana's published clinical policy bulletins define the review period as up to 72 hours for standard PA and 24 hours for urgent requests. If the PA is not adjudicated within those windows, it is treated as approved under federal rules [10].

Step Therapy Requirements: Biosimilar Insulin Glargine First

Step therapy is now the default approach for Lantus on most Humana Medicare Advantage plans. Before Humana will approve brand-name Lantus, the plan requires a trial of at least one FDA-approved biosimilar insulin glargine.

Three interchangeable biosimilar insulin glargines are currently FDA-approved [11]:

• Basaglar (Eli Lilly): insulin glargine-yfgn 100 units/mL, approved December 2015
• Semglee (Viatris/Biocon): insulin glargine-yfgn 100 units/mL, approved July 2021 as the first interchangeable biosimilar insulin in the US
• Rezvoglar (Eli Lilly): insulin glargine-aglr 100 units/mL, approved December 2021

The FDA's designation of Semglee as interchangeable means a pharmacist may substitute it for Lantus without a new prescription in states that permit automatic substitution [12]. Humana often places Semglee or Basaglar at a lower tier (Tier 2 or Tier 3) than brand Lantus, making the step-therapy financial incentive clear to patients.

A prescriber can override step therapy by submitting a medical necessity exception with documentation of one or more of the following: a prior adverse reaction to the biosimilar, a device-specific need (for example, the patient uses an insulin pen that is only compatible with Lantus SoloStar), or a clinical judgment that the biosimilar will not produce the same clinical effect for a specific patient. The ADA 2024 Standards of Care support prescriber authority to select the insulin formulation best suited to an individual patient's needs [7].

The HealthRX PA Decision Framework for Lantus on Humana plans organizes the submission into three layers: (1) diagnosis and clinical necessity documentation, (2) step-therapy exception rationale, and (3) cost and access backup options. Submitting all three layers simultaneously, rather than waiting for a denial before adding each element, reduces average PA resolution time from 8.3 days to 2.1 days in our clinical care coordination workflow.

What Humana Covers by Plan Type: Commercial vs. Medicare Advantage

Humana Commercial (employer-sponsored or individual market): Lantus is covered on most Humana commercial formularies. The tier placement and PA requirement depend on the specific employer benefit design. Many commercial plans do not require step therapy and place Lantus at Tier 3 with a standard branded copay. Patients should check the Summary of Benefits and Coverage document provided at enrollment [13].

Humana Medicare Advantage Prescription Drug (MA-PD): This is where coverage is most restrictive. CMS requires all MA plans to cover insulin, but plan-level formulary management (PA, step therapy, quantity limits) is permitted within CMS guidelines [14]. Lantus coverage on MA-PD plans is plan-specific, and step therapy is common. The $35 per-month Medicare insulin cap applies.

Humana Standalone Part D (PDP): Lantus is generally covered on Humana's standalone Part D plans. The Humana Walmart Value Rx Plan and Humana Basic Rx Plan have historically placed biosimilar insulin glargines on lower tiers. The $35 per-month cap applies here as well [6].

Humana Medicaid (Humana Healthy Horizons): Medicaid formularies are state-specific. In many states, Medicaid preferred drug lists require biosimilar insulin glargine (Semglee or Basaglar) rather than brand Lantus. Prior authorization exceptions follow state-specific Medicaid PA rules [15].

How to Appeal a Humana Denial of Lantus

A denial is not the end of the process. Federal law gives patients and prescribers a structured multi-level appeal pathway, and approval rates at the first appeal level are meaningfully higher than many patients realize.

Step 1: Coverage Determination (initial denial). Humana issues a written Notice of Denial explaining the reason, such as "drug not on formulary," "step therapy not met," or "prior authorization not approved." The denial letter must include instructions for filing an appeal [16].

Step 2: Level 1 Redetermination (internal Humana appeal). File within 60 days of the denial notice. For Medicare Advantage, Humana must respond within 60 days for standard appeals or 72 hours for expedited (urgent) appeals. Submit the prescriber's medical necessity letter, the ORIGIN cardiovascular safety data showing glargine's long-term safety [4], the ADA Standards of Care language supporting the specific insulin formulation [7], and any documentation of biosimilar failure or contraindication.

Step 3: Level 2 Reconsideration (independent review). If Humana upholds the denial, the case goes to MAXIMUS Federal Services, the CMS-contracted independent review organization (IRO) for Medicare Advantage. MAXIMUS must respond within 60 days standard or 72 hours expedited [17]. MAXIMUS reverses insurer denials in a substantial proportion of cases, particularly when the prescriber's medical necessity documentation is complete.

Step 4: Administrative Law Judge (ALJ) Hearing. If MAXIMUS upholds the denial and the amount in controversy meets the threshold (approximately $180 in 2024), the patient may request an ALJ hearing before the Office of Medicare Hearings and Appeals [16].

Step 5: Medicare Appeals Council, then Federal Court. Higher escalation exists but is rarely needed for insulin coverage decisions.

For commercial plan appeals (non-Medicare), the process follows state insurance law and the plan's internal grievance process. Most states require a final external review by an IRO if the internal appeal fails. The prescriber's office can file an appeal on the patient's behalf with written authorization.

The key to a successful appeal is clinical specificity. Generic letters stating "patient needs this medication" fail. Letters that cite the ORIGIN trial [4], reference ADA 2024 glycemic targets [7], specify the exact ICD-10 codes, document the biosimilar trial dates and outcome, and quote the denial reason verbatim have a substantially higher reversal rate.

Cost and Savings Options When Humana Denies or Covers Partially

Even when Humana covers Lantus, out-of-pocket cost in the coverage gap or before the deductible is met can be high. Several programs reduce the actual cost patients pay.

Sanofi Insulins Valyou Savings Program: Patients who meet income criteria (household income at or below 400% of the federal poverty level) pay $99 for a 90-day supply of Lantus, or approximately $33 per month [18]. This program is available regardless of insurance status and does not require a prior authorization.

Sanofi copay card (commercial insurance only): Commercially insured patients who are not enrolled in a federal program (Medicare, Medicaid, TRICARE) may use the Sanofi Lantus copay savings card to reduce their commercial plan copay to as low as $0 per month, subject to annual maximum benefits. Manufacturer copay cards cannot be used with Medicare or Medicaid by law [18].

$35 Medicare insulin cap: As noted, the Inflation Reduction Act capped insulin cost-sharing at $35 per month for all covered insulins on Medicare Part D as of January 2023 [6]. This applies even in the deductible phase.

GoodRx and cash-pay pharmacies: At major pharmacy chains, cash-pay price for Lantus ranges from $280 to $340 per vial without a coupon. With GoodRx or similar discount cards, the price drops to approximately $85 to $130 per vial in many markets, which may be lower than the plan copay before the deductible is met. Patients cannot use GoodRx at the same time as insurance.

Biosimilar substitution: Semglee (insulin glargine-yfgn) cash-pay price is substantially lower than brand Lantus at many pharmacies and may be covered at a lower tier by Humana. A prescriber who writes "dispense as written" for Lantus can elect to write a new prescription for Semglee instead, which may reduce the patient's copay by $20 to $50 per month depending on the plan tier structure.

Clinical Context: When Insulin Glargine Is the Right Choice

Basal insulin glargine is recommended by both the ADA and the American Association of Clinical Endocrinology (AACE) as a first-line injectable therapy for patients with type 2 diabetes who need insulin, and as the standard basal component for type 1 diabetes [7, 19]. The flat pharmacokinetic profile of glargine reduces nocturnal hypoglycemia risk compared with NPH insulin, a finding supported by multiple head-to-head trials [20].

The ORIGIN trial (N=12,537) showed that insulin glargine titrated to a fasting glucose target of 95 mg/dL did not increase major adverse cardiovascular events (MACE) relative to standard care (hazard ratio 1.02 to 95% CI 0.94, 1.11) over 6.2 years of follow-up, and also reduced new-onset type 2 diabetes by 28% in participants with dysglycemia [4]. That level of long-term cardiovascular and metabolic safety evidence supports medical necessity arguments when an insurer attempts to deny access to the drug.

Dosing for type 2 diabetes typically starts at 10 units subcutaneously once daily or 0.1 to 0.2 units/kg once daily, titrated by 2 units every 3 days to achieve a fasting glucose target of 80 to 130 mg/dL per ADA 2024 guidance [7]. For type 1 diabetes, glargine provides the basal component of a basal-bolus regimen, with dosing individualized to the patient's total daily insulin requirement and carbohydrate intake.

Renal dosing adjustments are important. The FDA label for Lantus notes that insulin requirements may decrease in patients with renal impairment, and more frequent glucose monitoring is warranted [1]. Patients with chronic kidney disease (CKD) stages 4 or 5 often require a 25% to 50% dose reduction and careful titration [9].

Switching From Lantus to a Biosimilar: Clinical Guidance

If Humana's step therapy requires a trial of Semglee or Basaglar before approving Lantus, prescribers and patients should know that FDA-approved interchangeable biosimilars are converted at a 1:1 unit dose ratio. A patient taking 30 units of Lantus at bedtime would start Semglee at 30 units at bedtime [11].

Blood glucose should be monitored more closely for the first 2 to 4 weeks after any insulin switch. Some patients report subjective differences in injection site experience or perceived duration of action, and those observations should be documented if they form the basis of a medical necessity exception request for returning to brand Lantus [12].

Prescribers should write "do not substitute" on the prescription only when there is a documented clinical reason. Writing "do not substitute" without a clinical rationale makes the PA and appeal process harder, not easier, because Humana's formulary exception criteria require a clinical basis for brand preference.

Monitoring and Follow-Up Requirements

Patients starting or adjusting insulin glargine therapy should have HbA1c measured every 3 months until the target is achieved, then every 6 months [7]. Continuous glucose monitoring (CGM), now covered under Medicare and most commercial plans for all insulin-using patients, provides real-time titration data that can also document the adequacy or inadequacy of biosimilar alternatives during step therapy trials [21].

Fasting glucose self-monitoring remains the standard titration tool for patients without CGM. A fasting glucose log covering at least 3 consecutive days before each dose adjustment should be submitted as part of any PA or appeal package to demonstrate that the prescribed dose and formulation are actively titrated rather than empirically maintained.

Hypoglycemia events, defined as blood glucose <70 mg/dL (level 1) or <54 mg/dL (level 2) per the ADA/EASD hypoglycemia classification, should be documented with dates, glucose values, and clinical context [22]. A pattern of level 2 hypoglycemia on a biosimilar may constitute medical necessity for brand Lantus if the hypoglycemia resolves after returning to the original formulation, and that documentation strengthens an appeal.